Plaintiff
1 case as plaintiff.
Aquestive Therapeutics, Inc. (NASDAQ: AQST) is a publicly traded specialty pharmaceutical company founded in 2004 and headquartered in Warren, New Jersey. The company focuses on developing and commercializing products that utilize its proprietary PharmFilm® technology for drug delivery. As of December 2025, the company had 147 employees and reported trailing 12-month revenue of $44.5 million. Its market capitalization was approximately $539 million as of May 2026.
Aquestive Therapeutics is an operating company that leverages its proprietary PharmFilm® technology to deliver drugs through thin, dissolvable oral films. This technology is applied to new and existing molecules to improve patient outcomes and convenience. The company's commercialized products, marketed by licensees, include Sympazan® for seizures associated with Lennox-Gastaut Syndrome, Suboxone® for opioid dependence, and others for conditions like nausea and ALS. Aquestive is also advancing its own pipeline of proprietary product candidates, with a focus on treatments for severe allergic reactions (anaphylaxis) with its Anaphylm™ (epinephrine sublingual film) and other central nervous system (CNS) disorders. In addition to product development, the company offers contract development and manufacturing (CDMO) and packaging services to other pharmaceutical companies.
Based on the provided data, Aquestive Therapeutics acts as a plaintiff in patent matters. The single tracked case shows the company as a plaintiff in a 2025 proceeding before the Patent Trial and Appeal Board (PTAB) against Iono Pharma, LLC. This posture as a plaintiff is consistent with an operating company actively defending its intellectual property. Historically, the company has been involved in patent litigation to enforce its patents, including cases related to its Suboxone® sublingual film product. The company actively seeks patent protection for its products and technologies, such as its Anaphylm epinephrine film, to build and defend its market position.
Watchlist
Email-only, free, anonymous. We'll notify you when Aquestive Therapeutics, Inc. files another patent-infringement lawsuit. One-click unsubscribe from any alert.
Aquestive Therapeutics, Inc. filed an Inter Partes Review petition challenging the validity of claims 1-3 of the '437 patent as obvious. The Patent Trial and Appeal Board (PTAB) exercised its discretion and denied the institution of the IPR.